Previsioni di mercato dei prodotti terapeutici per le malattie infettive nell\'Asia del Pacifico fino al 2030 - Analisi regionale - per classe di farmaci (antivirali, antibatterici, antifungini e altri), indicazione (HIV, epatite, tubercolosi, influenza, HPV e altri), percorso Di somministrazione (orale, parenterale, topica e altri) e canale di distribuzione (farmacie ospedaliere, farmacie al dettaglio e altri)

BMIRE00030366 | Pages: 101 | Pharmaceuticals | Jul 2024 | Type: Regional | Status: Published
Il mercato delle terapie per le malattie infettive dell’Asia del Pacifico è stato valutato a 25.904,61 milioni di dollari nel 2022 e si prevede che raggiungerà i 37.415,07 milioni di dollari entro il 2030; si stima che registrerà un CAGR del 4,7% dal 2022 al 2030.

Le crescenti opportunità nei paesi in via di sviluppo stimolano il mercato terapeutico delle malattie infettive nell\'Asia del Pacifico.

Si prevede che la crescente incidenza delle malattie infettive aumenterà il vendite di farmaci terapeutici per malattie infettive nei paesi in via di sviluppo. L’Asia del Pacifico è diventata un hub adattabile e favorevole alle imprese grazie a requisiti di dati moderatamente inferiori e normative rigorose. Inoltre, gli elevati investimenti nella ricerca sanitaria e nelle scienze della vita nei paesi emergenti svolgono un ruolo chiave nella promozione delle ultime tecnologie nei paesi in via di sviluppo, il che, a sua volta, sostiene la tendenza verso la diagnosi e il trattamento delle malattie infettive. L’UNAIDS, ad esempio, chiede un investimento di 29 miliardi di dollari entro il 2025 per soddisfare le esigenze dei paesi a basso e medio reddito nella risposta all’AIDS. Pertanto, si prevede che i produttori cruciali di prodotti terapeutici per malattie infettive nei mercati emergenti di prodotti terapeutici per malattie infettive in India e Corea del Sud saranno testimoni di opportunità redditizie in futuro. Ciò è dovuto all’elevata prevalenza di malattie infettive come l’epatite, l’HAI, l’HIV e l’influenza; una vasta popolazione di pazienti; un aumento del reddito disponibile della popolazione; miglioramento delle infrastrutture sanitarie; e la crescita del turismo medico in questi paesi.

Panoramica del mercato dei prodotti terapeutici per le malattie infettive nell\'Asia del Pacifico

Il mercato dei prodotti terapeutici per le malattie infettive nell\'Asia del Pacifico è suddiviso in Cina, India, Giappone, Corea del Sud, Australia e nel resto dell\'Asia del Pacifico. Si prevede che l’Asia Pacifico registrerà il CAGR più rapido durante il periodo di previsione. Si prevede che il mercato nella regione crescerà a causa dell’aumento della spesa sanitaria globale, della crescente incidenza di malattie croniche e infettive e della crescente base della popolazione geriatrica. Le malattie infettive come l\'influenza, l\'epatite B e la diarrea infettiva sono comuni in Cina, mentre il tifo, la malaria, l\'itterizia, la tubercolosi e l\'AIDS in India. L’influenza, l’epatite B e la diarrea infettiva sono le tre malattie infettive più comuni in Cina. Come affermato da Frontiers Public Health, il picco invernale dell’influenza è coinciso con l’epidemia di COVID-19 nel paese nel 2021. Secondo il Direttore Paese Cina 2020 della Banca Mondiale, il paese è ad alto rischio di malattie infettive a causa della sua popolazione in crescita, abbondanza di fauna selvatica, frammentazione degli habitat e alti livelli di produzione di bestiame. Considerando la crescente incidenza di malattie infettive nel Paese, il Consiglio dei direttori esecutivi della Banca mondiale ha approvato un prestito di 300 milioni di dollari per il progetto di prevenzione, preparazione e risposta alle malattie infettive emergenti. Ciò lo aiuterà a ridurre il rischio di zoonosi e altre minacce sanitarie emergenti. Pertanto, si prevede che la crescente incidenza delle malattie infettive e le misure adottate per controllare queste malattie aumenteranno il mercato cinese delle terapie per le malattie infettive nei prossimi anni.

Entrate e previsioni del mercato dei prodotti terapeutici per le malattie infettive nell\'Asia del Pacifico fino al 2030 (milioni di dollari)

Segmentazione del mercato dei prodotti terapeutici per le malattie infettive nell\'Asia del Pacifico

Il mercato dei prodotti terapeutici per le malattie infettive nell\'Asia del Pacifico è classificato in categorie in classe di farmaco, indicazione, via di somministrazione, canale di distribuzione e paese.

In base alla classe di farmaci, il mercato delle terapie per le malattie infettive dell\'Asia Pacifico è segmentato in antivirali, antibatterici, antifungini e altri. Il segmento antivirale ha detenuto la quota di mercato maggiore nel 2022.

In termini di indicazione, il mercato delle terapie per le malattie infettive dell\'Asia del Pacifico è segmentato in HIV, epatite, tubercolosi, influenza, HPV e altri. L\'HIV ha detenuto la quota di mercato maggiore nel 2022.

In base alla via di somministrazione, il mercato delle terapie per le malattie infettive dell\'Asia del Pacifico è segmentato in orale, parenterale, topico e altri. Il segmento orale ha detenuto la quota di mercato maggiore nel 2022.

In termini di canale di distribuzione, il mercato delle terapie per le malattie infettive dell\'Asia del Pacifico è segmentato in farmacie ospedaliere, farmacie al dettaglio e altri. Le farmacie ospedaliere detenevano la quota di mercato maggiore nel 2022.

Per paese, il mercato delle terapie per le malattie infettive nell\'Asia del Pacifico è segmentato in Cina, Giappone, India, Australia, Corea del Sud e resto dell\'Asia del Pacifico. Nel 2022 la Cina ha dominato la quota di mercato delle terapie per le malattie infettive nell\'Asia del Pacifico.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc e Shionogi & Co Ltd sono alcune delle aziende leader che operano nel mercato delle terapie per le malattie infettive dell\'Asia del Pacifico.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics

4.1 Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics

4.2 Market Drivers

4.2.1 Rising Prevalence of Infectious Disease

4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics

4.3 Market Restraints

4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects

4.4 Market Opportunities

4.4.1 Growing Opportunities in Developing Nations

4.4.2 Escalating Threat of Antibiotic Resistance

4.5 Future Trends

4.5.1 Rising Number of Product Approvals and Launches

4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - Asia Pacific Market Analysis

5.1 Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Drug Class

6.1 Overview

6.2 Anti-Viral

6.2.1 Overview

6.2.2 Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.3 Anti-bacterial

6.3.1 Overview

6.3.2 Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.4 Anti-fungal

6.4.1 Overview

6.4.2 Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.5 Others

6.5.1 Overview

6.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Indication

7.1 Overview

7.2 HIV

7.2.1 Overview

7.2.2 HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Hepatitis

7.3.1 Overview

7.3.2 Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Tuberculosis

7.4.1 Overview

7.4.2 Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Influenza

7.5.1 Overview

7.5.2 Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.6 HPV

7.6.1 Overview

7.6.2 HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.7 Others

7.7.1 Overview

7.7.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Route of Administration

8.1 Overview

8.2 Oral

8.2.1 Overview

8.2.2 Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Parenteral

8.3.1 Overview

8.3.2 Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Topical

8.4.1 Overview

8.4.2 Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.5 Others

8.5.1 Overview

8.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Distribution Channel

9.1 Overview

9.2 Hospital Pharmacies

9.2.1 Overview

9.2.2 Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9.3 Retail Pharmacies

9.3.1 Overview

9.3.2 Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9.4 Others

9.4.1 Overview

9.4.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Infectious Disease Therapeutics Market - Country Analysis

10.1 Asia Pacific Infectious Disease Therapeutics Market Overview

10.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country

10.1.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country

10.1.1.2 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.2.1 Overview

10.1.1.3 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.3.1 China: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.3.2 China: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.3.3 China: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.3.4 China: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.4 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.4.1 Overview

10.1.1.5 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.5.1 Japan: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.5.2 Japan: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.5.3 Japan: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.5.4 Japan: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.6 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.6.1 Overview

10.1.1.7 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.7.1 India: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.7.2 India: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.7.3 India: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration

10.1.1.7.4 India: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.8 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.8.1 Overview

10.1.1.9 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.9.1 Australia: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.9.2 Australia: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.9.3 Australia: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration

10.1.1.9.4 Australia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.10 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.10.1 Overview

10.1.1.11 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.11.1 South Korea: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.11.2 South Korea: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.11.3 South Korea: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.11.4 South Korea: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.12 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.12.1 Overview

10.1.1.13 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.13.1 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.13.2 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.13.3 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.13.4 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

11.1 Overview

11.2 Growth Strategies in the Infectious Disease Therapeutics Market

11.3 Inorganic Growth Strategies

11.3.1 Overview

11.4 Organic Growth Strategies

11.4.1 Overview

12. Company Profiles

12.1 Pfizer Inc

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Gilead Sciences Inc

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 F. Hoffmann-La Roche Ltd

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Shionogi & Co Ltd

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Bayer AG

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 GSK Plc

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 AbbVie Inc

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Merck & Co Inc

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 Astellas Pharma Inc

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

13. Appendix

13.1 About The Insight Partners

List of Tables

Table 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation

Table 2. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class

Table 3. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication

Table 4. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 5. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 6. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country

Table 7. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 8. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 9. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 10. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 11. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 12. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 13. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 14. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 15. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 16. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 17. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration

Table 18. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 19. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 20. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 21. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration

Table 22. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 23. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 24. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 25. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 26. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 27. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 28. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 29. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 30. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market

Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List of Figures

Figure 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation, by Country

Figure 2. Impact Analysis of Drivers and Restraints

Figure 3. Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

Figure 4. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)

Figure 5. Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 6. Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)

Figure 10. HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 11. Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 15. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)

Figure 17. Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 19. Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 20. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 21. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 22. Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 23. Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 24. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 25. Asia Pacific Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)

Figure 26. Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 27. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 28. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 29. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 30. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 31. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 32. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market

1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. F. Hoffmann-La Roche Ltd
5. Gilead Sciences Inc
6. GSK Plc 
7. Merck & Co Inc
8. Pfizer Inc
9. Shionogi & Co Ltd

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific infectious disease therapeutics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific infectious disease therapeutics market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440